TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03601949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: physical therapy, medications, lifestyle changes
Study: NCT02411214

Intervention type: OTHER
Intervention: survey
Description: questionnaire survey sent by regular mail for 3 groups

Intervention type: OTHER
Intervention: survey
Description: questionnaire survey sent by regular mail for 3 groups

Intervention type: OTHER
Intervention: survey
Description: questionnaire survey sent by regular mail for 3 groups
Study: NCT02772445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STROKE-CARE
Description: In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
Study: NCT04206384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultimate Contour Body Sculpting Device
Study: NCT01600235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
Study: NCT06176378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional pulpotomy
Description: After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser pulpotomy
Description: after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
Study: NCT04788277

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of urine samples
Study: NCT02112578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: 25 mg, 3 times per day up to 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: 50 mg, 3 times per day up to 30 days
Study: NCT04509609

Intervention type: OTHER
Intervention: Any other mutation in SGBC gene
Description: Any patient affected by LGMD 2E with a genetic diagnosis other than the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
Study: NCT02563483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga and compassion meditation program
Description: 25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
Study: NCT04330248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive single oral dose of erdafitinib tablets on Day 1 in Period 1 and on Day 28 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive an oral dose of carbamazepine tablets from Day 15 to 35 in Period 2.
Study: NCT03248856

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: Intratympanic administration

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: Intratympanic administration
Study: NCT02924896

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soybean oil
Description: 60g of soybean oil will be given in a milkshake at breakfast
Study: NCT04175795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Personal Brain Health Dashboard
Description: The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors.
Study: NCT01820559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 1200 mg
Description: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESL 800 mg
Description: Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
Study: NCT01137188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Description: Low calorie diet containing 800-1000 kcal/day
Study: NCT02486601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel : 150 mg/m2 D1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
Study: NCT00541918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan (propofol, Astra Zeneca)
Description: Total intravenous anesthesia with propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane (sevoflurane, Abbott)
Description: inhaled anesthesia with sevoflurane
Study: NCT00085202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT02754687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11βmethyl nortestosterone dodecylcarbonate
Description: Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
Study: NCT00849511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
Study: NCT00085202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT02360150

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: second propeller arm scanner
Description: The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
Study: NCT04858061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cue Exposure Therapy
Description: Exposure to alcohol-related cues within virtual environments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Pharmacotherapy and psychotherapy
Study: NCT00626821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: Real life assessment of SenSura
Study: NCT02448537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01758731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
Study: NCT03953495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together
Description: The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
Study: NCT02348801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and Exercise
Description: Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of \~90 min duration 15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and, after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: Diabetes support and education
Study: NCT01340027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT04191369

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard.
Study: NCT01728818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² d1,8,15 q4weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg flat dose, po, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m², d1,8,15 q4weeks
Study: NCT00085202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
Study: NCT01860469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vancomycin-soaked mesh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plain mesh
Study: NCT02571270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance physical training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance physical training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance physical training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance physical training program
Study: NCT00628901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Fibroid Embolization (UFE)
Description: Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Fibroid Embolization (UFE)
Description: Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour SE™ Microspheres
Description: Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embosphere® Microspheres
Description: Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
Study: NCT00894673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium Hipolabor
Description: Heparin sodium Hipolabor 5.000 UI/mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium APP
Description: Heparin sodium APP 5.000 USP
Study: NCT02889133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron-dextran
Description: Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron-dextran
Description: Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Salt water IV - 500 mL, one pint normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Salt water IV - 500 mL, one pint normal saline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Donation
Description: Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Donation
Description: Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour PTR
Description: The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 24-hour PTR
Description: The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation.
Study: NCT02304276

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluoride PET-CT
Description: Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluoride PET-CT
Description: Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluoride PET-CT
Description: Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT calcium score of aortic valve
Description: CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT calcium score of aortic valve
Description: CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
Study: NCT02265614

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGS
Study: NCT01060553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
Study: NCT01546259

Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.